Veraxa Biotech is trading 7.33% up in pre-market at $1.21, compared with its October 5 close of $1.13; no clear overnight catalyst was identified. - The provided price history shows a sustained decline over the preceding sessions. - The latest company-specific headlines were earlier announcements, including financing news; no new company announcement surfaced for October 6. - Major US indices were only modestly higher, with insufficient evidence to attribute the move to broader market sentiment.